Quick Answer
Sigyn Therapeutics, Inc. reported Operating Income Loss of -$2.52 million for the year ending 2024.
- Sigyn Therapeutics, Inc. showed a decrease of -2.6% in Operating Income Loss from 2023 to 2024.
- This data is from Sigyn Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2014 to 2024 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$151.8 thousand | Q2 2015: -$483.3 thousand | Q3 2015: -$816.6 thousand | Q1 2016: -$712.7 thousand | Q2 2016: -$526.9 thousand | Q3 2016: -$329.4 thousand | Q1 2017: -$344.2 thousand | Q2 2017: -$615.3 thousand | Q3 2017: -$580.2 thousand | Q1 2018: -$288.2 thousand | Q2 2018: -$233.1 thousand | Q3 2018: -$241.3 thousand | Q1 2019: -$168.9 thousand | Q2 2019: -$101.3 thousand | Q3 2019: -$122.7 thousand | Q4 2019: -$1.6 thousand | Q1 2020: -$193.0 thousand | Q2 2020: -$175.9 thousand | Q3 2020: -$203.0 thousand | Q1 2021: -$402.1 thousand | Q2 2021: -$441.8 thousand | Q3 2021: -$573.4 thousand | Q1 2022: -$609.2 thousand | Q2 2022: -$532.8 thousand | Q3 2022: -$533.6 thousand | Q1 2023: -$521.3 thousand | Q2 2023: -$574.0 thousand | Q3 2023: -$642.8 thousand | Q1 2024: -$630.0 thousand | Q2 2024: -$602.8 thousand | Q3 2024: -$808.5 thousand | Q1 2025: -$546.1 thousand | Q2 2025: -$469.5 thousand | Q3 2025: -$386.5 thousand.
- Over the full 10 years of available data (2014 to 2024), Sigyn Therapeutics, Inc.'s Operating Income Loss has declined by 550.1%.
- Historical annual values: Fiscal year 2024: -$2.52 million | Fiscal year 2023: -$2.46 million | Fiscal year 2022: -$2.15 million | Fiscal year 2021: -$2.01 million | Fiscal year 2020: -$916.4 thousand | Fiscal year 2019: -$518.0 thousand | Fiscal year 2018: -$1.00 million | Fiscal year 2017: -$2.03 million | Fiscal year 2015: -$2.25 million | Fiscal year 2014: -$387.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: